Arovella Therapeutics Ltd (Arovella), based in Australia and the US, is a world leader in reformulating and delivering medication through the oral mucosa.
Patients typically take medication as pills, tablets or capsules yet less than 25% of the medication is absorbed into the bloodstream.
Arovella can increase the bioavailability of administered medications, which means it increases the amount of the drug absorbed by the body so is able to increase the effect of that drug.
Arovella has increased bioavailability up to 95%. This is a major step forward in the evolution of drug delivery technology.
MELBOURNE, AUSTRALIA 28 April 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray deliver…
Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat blood cancers, is pleased to announce that it has agr…